Apple Turns 50: From Garage Startup to AI Crossroads 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
EAST RUTHERFORD, N.J., July 31, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that second quarter 2017 financial results will be released on Friday, August 4, 2017 before the market opens.
The Company will host a conference call to discuss the financial results.
| Second Quarter 2017 Earnings Conference Call | ||
| When: | Friday, August 4, 2017 at 8:30 a.m. Eastern Time | |
| Dial-in: | 1-866-548-4713 for U.S. | |
| 1-323-794-2093 for International | ||
| Passcode: 3908726 | ||
| Dial-in Replay: | 1-888-203-1112 for U.S. | |
| 1-719-457-0820 for International | ||
| Passcode: 3908726 | ||
| Available through Friday, August 11, 2017 | ||
| Webcast: | www.cambrex.com | |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201-804-3037 Email: [email protected]
